中国临床药学杂志

目的 探讨屈螺酮/炔雌醇联合坤泰胶囊治疗多囊卵巢综合征的疗效。方法 选取2021年1月至2022年12月就诊的86例多囊卵巢综合征患者为研究对象，随机分为对照组和研究组各43例。对照组予屈螺酮/炔雌醇治疗，研究组予屈螺酮/炔雌醇联合坤泰胶囊治疗，比较2组临床疗效、中医证候评分、排卵及妊娠情况和性激素水平。结果 研究组总有效率(90.70%)高于对照组(69.77%)，差异有统计学意义(P <0.05)。治疗后，研究组经行先期、量少色红、五心烦热、咽干口渴、头晕心悸、腰酸腿软中医证候积分均低于对照组(P <0.05)；排卵率及妊娠率均高于对照组(P <0.05)；血清雌二醇(E₂)和卵泡刺激素(FSH)水平高于对照组(P <0.05)，黄体生成素(LH)和睾酮(T)水平低于对照组(P <0.05)。结论 屈螺酮/炔雌联合坤泰胶囊能够提高多囊卵巢综合征患者的疗效，改善临床症状和性激素水平，提高排卵率和妊娠率，值得临床推广。

AIM To compare the curative effect of drospirenone and ethinyl estradiol combined with Kuntai capsule on patients with polycystic ovary syndrome. METHODS A total of 86 patients with polycystic ovary syndrome were as the study subjects and randomly separated into reference group and research group, with 43 patients in each group. Patients in the reference group were treated with drospirenone and ethinyl estradiol, and patients in the research group were treated with drospirenone and ethinyl estradiol combined with Kuntai capsules. The efficacy, traditional Chinese medicine(TCM) syndrome score, ovulation,pregnancy and sex hormone levels of 2 groups were compared. RESULTS The total effective rate of research group was 90.70%,which was higher than 69.77% of reference group, with a significant difference(P < 0.05). After treatment, the TCM syndrome scores of early menstruation, low volume, red color, five upset heat, dry throat, thirst, dizziness, palpitation, lumbago and leg weakness in the study group were lower than those in the control group(P < 0.05). The ovulation rate and pregnancy rate of research group were higher than those of reference group(P < 0.05). After treatment, the levels of serum estradiol(E₂) and follicle stimulating hormone(FSH) in research group were higher than those in reference group(P < 0.05), and the levels of luteinizing hormone(LH) and testosterone(T) were lower than those in reference group(P < 0.05). CONCLUSION Drospirenone and ethinyl estradiol combined with Kuntai capsules can improve the therapeutic effect, promote the ovulation rate and pregnancy rate in patients with polycystic ovary syndrome, which is worthy of clinical application.